News | October 10, 2024
India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh
We now rank 3rd in pharmaceutical production by volume and 14th by value
We now rank 3rd in pharmaceutical production by volume and 14th by value
Lack of technology transfer stands out as a formidable barrier
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Affordability is key to providing accessible healthcare for Bharat.
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Subscribe To Our Newsletter & Stay Updated
